Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 149

  • 74

  • 24

  • 18

  • 15

  • 14

  • 12

  • 10

  • 10

  • 9

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for


Combatting Bladder Cancer by Inducing Epithelial Turnover

Funder: National Cancer Institute

Funding period
USD 204 K
Funding amount
Abstract Bladder cancer is the 5th most frequent cancer in the US1. The most common histologic type of bladder cancer is urothelial carcinoma and it presents often as non-muscle invasive (NMIBC) form. The initial treatment for NMIBC is transurethral resection (TUR). However, over 70% of these patients will develop tumor recurrence with 25% showing progression to muscle-invading disease within 5 years of TUR. Currently, intravesicular BCG-based immunotherapy and chemotherapy are widely used as adjuvant therapies after TUR, but their effectiveness is limited, due to side effects and/or the inability of therapeutic agents to penetrate the bladder mucosa. Thus there exists a dire need for new strategies as adjunct therapy for bladder cancer. Recently, the whole scale exfoliation of the superficial epithelium mediated by the bladder to reduce bacterial numbers during infection was found to be a specific mast cell (MC) mediated activity. Further it was possible to activate whole scale exfoliation of the bladder epithelium by merely administering a MC activator in the bladder lumen. Although a highly efficient re-epithelization program exists for bladder epithelium recovery, addition of a GAG layer to the exposed bladder wall soon after exfoliation was found to significantly enhance the speed and intensity of bladder recovery. In view of this ability to trigger rapid turnover of the bladder epithelium, we hypothesize that safely inducing bladder epithelial turnover is a powerful way to prevent recurrence of bladder cancer. Here we plan to Investigate if inducing epithelial turnover with MC activators in the bladder will reduce/eliminate tumors in the bladders of mice. We will also Investigate if administering a GAG matrix containing growth promoting and/or anti-inflammatory agents will accelerate reepithelization following induced epithelial loss.

USD 201.0 M
Aggregated funding amount
USD 622 K
Average funding amount
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 135,849
2019 - 2021
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, ARUN SHARMA, JOHN ROGERS

USD 709,004
2019 - 2023
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Role of Fgfr2 signaling in bladder injury and regeneration

National Institute of Diabetes and Digestive and Kidney Diseases to CARLTON MATTHEW BATES

USD 234,750
2019 - 2022
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Identifying Immunological Basis for Bladder Cancer Sex Bias

Canadian Institutes of Health Research to Hyunwoo Kwon, Zihai Li

USD 26,219
2019 - 2022
Project list item
[Development of myeloid-derived suppressor cells (MDSC) targeted therapy for the treatment of bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to 祐士 武山

USD 38,322
2019 - 2023
Project list item
New zebrafish-based methods for prediction of cisplatin response in bladder cancer

VINNOVA to Lasse Jensen

USD 33,577
2019 - 2019
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research

National Cancer Institute to KIM N DANFORTH

USD 172,270
2019 - 2021
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 410,835
2019 - 2024
Project list item
A revolutionary shape memory alloy-based disposable device for bladder cancer removal

European Commission

USD 57,207
2019 - 2019
Project list item
Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

German Research Foundation to Stefan Garczyk, Nadine Gaisa

2019 -
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
load more...